Zilebesiran for Uncontrolled Hypertension and Heart Risk

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Recruiting Phase 3 Interventional Study
High Risk Cardiovascular Disease Hypertension High Cardiovascular Risk
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
11,000 (estimated)
Sponsor
Alnylam Pharmaceuticals · Industry
Who this trial is looking for

This trial is looking for adults with high blood pressure that is not well controlled and have either a history of heart disease or are at high risk for heart disease. Participants will receive either the study drug, zilebesiran, or a placebo to see if it lowers the risk of serious heart-related events.

Are You a Good Fit for This Trial?
Must be taking Antihypertensive medication

You may be able to join if

  • I am 18 years or older with heart disease
  • I am 55 years or older with high risk for heart disease
  • I have heart disease or high risk for heart disease
  • I have high blood pressure that is treated with stable medicine

You may not be able to join if

  • I have a history of secondary hypertension
  • I have symptoms of orthostatic hypotension
  • My liver enzyme levels are very high
  • My bilirubin levels are too high
  • My blood clotting levels are too high
  • My potassium levels are too high
  • My kidney function is very low

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Is 18 years or older for patients with established cardiovascular disease (CVD) * Is 55 years or older for patients with high risk for CVD * Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD * Has treated hypertension…
Contacts

Clinical Trial Information Line

1-877-ALNYLAM

clinicaltrials@alnylam.com

CONTACT

Clinical Trial Information Line

1-877-256-9526

clinicaltrials@alnylam.com

CONTACT